Serum S100B Levels and Major Depressive Disorder: Its Characteristics and Role in Antidepressant Response by Jang, Byong-Su et al.
 
 
 
 
online © ML Comm  
www.psychiatryinvestigation.org 193 
0ORIGINAL ARTICLE0 
Print  ISSN 1738-3684 / On-line  ISSN 1976-3026
Copyright ⓒ 2008 Official Journal of Korean Neuropsychiatric Association
Psychiatry Invest 2008;5:193-198 
 
Serum S100B Levels and Major Depressive Disorder:  
Its Characteristics and Role in Antidepressant Response 
 
 
 
ObjectiveᄏS100B is a neurotrophic factor that is involved in neuroplasticity. Neuroplas-
ticity is disrupted in depression; however, treatment with antidepressants can restore neu-
roplasticity. S100B has previously been used as a biological marker for neuropathology 
and neuroplasticity; therefore, in this study, we compared serum S100B levels in depressive 
patients to those of normal controls. In addition, we compared the serum S100B levels of 
antidepressant responders to those of nonresponders. 
MethodsᄏThirty five normal controls and 59 depressive patients were enrolled in this study. 
Depressive patients entered a 6 week clinical trial that included treatment with antidepres-
sants. The serum S100B levels and clinical assessments, which included Hamilton depression 
rating scores, were measured at baseline and after 6 weeks of treatment with antidepressants. 
The difference in the serum S100B levels between depressive patients and normal controls 
and between antidepressant responders and nonresponders was then compared. 
ResultsᄏThere were no significant differences in the serum S100B levels of normal controls 
and depressive patients. In addition, 30 of the depressive patients responded to antidepres-
sant treatment while 29 did not. Finally, the responders had significantly higher baseline 
serum S100B levels than the nonresponders. 
ConclusionᄏThe results of this study suggest that the baseline serum S100B level is asso-
ciated with the subsequent response to antidepressants. In addition, the high baseline serum 
S100B level that was observed in depressive patients may enhance neuroplasticity, which 
results in a favorable therapeutic response to antidepressants. 
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Introduction 
 
Several recent studies have reported that a change in neuroplasticity is associated
with the pathophysiology of depression. In depressive patients, the serum levels of growth
factors are decreased,
1 and neuroplasticity, a fundamental mechanism of neuronal 
adaptation, is disrupted. In addition, recovery from depression is also associated with
neuroplasticity,
2-4 and the time lag that occurs between the administration of antidepres-
sants and the onset of therapeutic activity suggests that the therapeutic effect of antide-
pressants arises from enhanced neurogenesis and the induction of neuroplasticity.
2-9
S100B, which is one of the proteins involved in neuroplasticity,
10,11 is located in 
glial cells in the human brain.
12 SB100B is produced and secreted by astrocytes, and 
exerts paracrine and autocrine effects on neurons and glia.
13 In addition, S100B is an 
acidic Ca
2+ binding protein that may influence several cellular responses along the
Ca
2+-signal transduction pathway.
10,13,14 Additionally, S100B regulates cell shape, con-
traction, cell-to-cell communication, energy metabolism, intracellular signal transduc-
tion, and cell growth.
15 Cell culture and animal experiments have shown that the effects
of extracellular S100B depend on its concentration.
10,16 For example, when it is present 
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in nanomolar concentrations, S100B acts as a growth and 
differentiation factor for neurons and astrocytes. However, 
when it is present in micromolar concentrations, S100B 
exerts neurotoxic activity and induces the apoptosis of 
neurons and astrocytes. 
Several studies have reported that depressive patients 
have increased levels of S100B in the serum and cerebro-
spinal fluid (CSF).
17-20 For example, Rothermundt et al. 
reported that the serum S100B levels in depressive patients 
were higher than those in normal controls, and suggested 
that a high level of serum S100B might correspond to neu-
ron growth and synaptogenesis during synaptic remodeling 
in depressive patients.
17 Additionally, Arolt et al. reported 
that antidepressant responders had higher baseline serum 
S100B levels than nonresponders, and suggested that high 
serum S100B levels were related to a favorable therapeutic 
response.
19 The results of these previous studies suggest 
that S100B participates in neuroplasticity, which is im-
portant in recovery from depression. Furthermore, these 
findings indicate that the serum S100B level can be used 
to predict an antidepressant treatment response. 
In this study, we compared the serum S100B levels of 
depressive patients to those of normal controls. We also 
assessed the serum S100B levels of depressive patients 
before and after treatment with antidepressants and then 
compared the serum S100B levels of antidepressant res-
ponders to those of nonresponders. 
 
Methods 
 
Subjects 
Fifty-nine depressive patients that participated in the 
Clinical Trials Program of the Samsung Medical Center 
Affective Disorder Clinic were enrolled in this study. Pa-
tients received a semistructured diagnostic interview
21 
using the Korean version of the Diagnostic and Statistical 
Manual of Mental Disorders, Fourth Edition (DSM-IV),
22 
and all patients fulfilled the DSM-IV criteria for major 
depressive disorder. Diagnoses were confirmed by a board 
certified psychiatrist. Exclusion criteria for this study in-
cluded significant medical conditions, schizophrenia or 
other psychotic disorders, bipolar disorder, a history of 
alcohol or drug dependence, epilepsy, and organic mental 
disorders. All patients enrolled in this study were at least 
18 years of age. 
Normal controls were recruited by advertisement in 
local newspapers. Normal controls met the following cri-
teria: a Beck depression inventory (BDI)
23 score of less 
than 16; a score on the Korean version of the mini mental 
status exam (K-MMSE)
24 within the normal limits for 
their age and education level; a 7 Minute Screening battery 
score
25 within normal limits for their age and education 
level; a Seoul-Activities of Daily Living (S-ADL)
26 score 
of 0, and a Seoul-Inventory Activities of Daily Living (S-
IADL)
26 score that was less than 8; no abnormal neuro-
logical signs. Normal controls were excluded based on 
the Healthy Screening Exclusion Criteria.
27 Thirty five 
normal healthy controls were enrolled in this study. 
The study protocol was approved by the institutional 
review board of Samsung Medical Center, Seoul, Korea. 
Signed informed consent was obtained from all partici-
pants. 
 
Procedure 
We obtained blood samples by venipuncture and then 
measured the serum S100B levels. In depressive patients, 
blood samples were obtained prior to treatment with anti-
depressants (baseline S100B) and after 6 weeks of treat-
ment with antidepressants (S100B after treatment). 
The severity of the depressive symptoms was rated 
using the 17-item Hamilton Rating Scale for Depression 
(HAM-D),
23 which was administered by a single trained 
rater. The 17-item HAM-D scores were obtained at base-
line and after 6 weeks of antidepressant treatment. A res-
ponse was defined as a decrease in the HAM-D score of 
50% or more at 6 weeks. 
The rater and laboratory workers were blind to the 
purpose of the study. In addition, the rater was blind to 
the S-100B data, and the HAM-D scores were not disclosed 
to the laboratory workers. To maintain blindness, a trained 
research coordinator managed all data and schedules. 
The clinician’s drug choice was based on the anticipated 
side effects and the symptomatic characteristics of the 
patients. The dosing protocol was flexible and conducted 
according to the clinician’s assessment of symptoms and 
side effects. Side effects were measured using the UKU 
Side Effect Rating Scale
28 at each visit. Anxiolytics and 
sedative-hypnotics were permitted. 
 
Biochemical assay 
Venous blood was drawn using a serum-separating tube 
(SST) vacutainer, after which it was allowed to stand at 
room temperature for 30 min. The samples were then cen-
trifuged at 3,000 rpm for 15 min, after which the serum 
supernatant was collected and frozen at -80℃ until  as-
say. Qutantitation of the S100B serum levels was con-
ducted using a CanAg S100 Enzyme immunometric assay 
kit (CanAg Diagnostics AB, Sweden) according to the 
manufacturer’s instructions. This solid-phase, two-step, 
non-competitive immunoassay kit is based on two mouse 
monoclonal antibodies specific for two different epitopes 
expressed in S100B (S100A1B+S100BB). Briefly, cali-
brators and samples were incubated together with biotiny-
lated Anti-S100B monoclonal antibody in Streptavidin  
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coated microtiter strips. S100B present in the calibrators 
or samples was then adsorbed to the Streptavidin coated 
microtiter wells by the biotinylated anti-S100B monoclonal 
antibody during incubation. The strips were then washed 
and incubated with horseradish peroxidase (HRP) labeled 
Anti-S100B monoclonal antibody. Next, buffered Sub-
strate/Chromogen reagent (hydrogen peroxide and 3, 3’, 
5, 5’ tetra-methylbenzidine) was added to each well, which 
resulted in the enzyme reaction developing a blue color if 
antigen was present. After adding stop solution, the absor-
bance values were gotten at 405 nm. All analyses were 
conducted in duplicate in a double-blind test using an 
electronic pipetter. The lower detection limit of the assay 
for S100 was 25 ng/L. The imprecision of the intraassay 
(within-run CVs) was 1.1% at 0.054 ug/L, 4.6% at 0.489 
ug/L, and 0.8% at 1.5 ug/L. The total imprecision (be-
tween-day, CVs) was 10.5% at 0.054 ug/L, 7.6% at 0.490 
ug/L, and 0.8% at 1.5 ug/L. 
 
Data analysis 
The means and standard deviations (SDs), ranges of 
continuous variables, and proportions of categorical va-
riables were determined. Specifically, a T-test was used 
to evaluate continuous variables and a χ
2 test was used 
for categorical variables. Accordingly, we compared the 
serum S100B levels of the depressive patients and normal 
controls using a T-test. Similarly, we compared the serum 
S100B levels of antidepressant responders and nonres-
ponders at baseline and after treatment using a T-test. We 
then used multiple logistic regression analysis to determine 
if the S100B levels were different between antidepressant 
responders and nonresponders after adjusting for sex, age, 
body mass index (BMI, weight/height
2), family history, 
episode numbers, onset age, and the duration of the cur-
rent episode. In this analysis, treatment response was con-
sidered to be a dependent variable. All differences were 
considered to be significant at p<0.05. 
Results 
 
Subject characteristics 
Of the 35 normal controls, 24 (69%) were female, and 
of the 59 depressive patients, 43 (73%) were female. The 
mean age of the normal controls was 61.8, and the mean 
age of the depressive patients was 60.3. The mean BMI 
of the normal healthy controls was 24.9 kg/m
2 and the 
mean age of the depressive patients was 24.1 kg/m
2. There 
were no significant differences in the mean sex ratio, age, 
or BMI of the depressive patients and the normal controls 
(Table 1). 
A total of 59 depressive patients received antidepres-
sants. Twenty two patients received mirtazapine, 29 pa-
tients received selective serotonin reuptake inhibitors 
(SSRIs)(fluoxetine, n=21; paroxetine, n=4; sertraline, 
n=3; and escitalopram, n=1), 3 patients received venla-
faxine, 2 patients received nortriptylline, 1 patient received 
bupropion, and 2 patients received agomelatine. Of the 59 
depressive patients, 30 were responders and 29 patients 
were nonresponders. Of the 30 responders, 14 received 
mirtazapine, 12 received SSRIs (fluoxetine, n=9; paroxe-
tine, n=2; and sertraline, n=1), 1 received nortriptylline, 
1 received bupropion, and 2 received agomelatine. Of the 
29 nonresponders, 8 received mirtazapine, 17 received 
SSRIs (fluoxetine, n=12; paroxetine, n=2; sertraline, n= 
2; and escitalopram, n=1), 3 received venlafaxine, and 1 
received nortriptylline. There were no differences in the 
mean sex ratio, age, BMI, family history, number of epi-
sodes, onset age, or duration of current episode between 
the responders and nonresponders (Table 1). 
 
Serum S100B levels 
The mean serum S100B level of the depressive patients 
was lower than that of the normal controls, but this dif-
ference was not statistically significant (64.1±20.4 ng/L 
and 69.6±16.4 ng/L, mean±SD for depressive patients 
TABLE 1. Demographic and clinical characteristics of study subjects
Depressive patients (N=59) 
Characteristics 
Normal controls   
(N=35)  All patients  AD responder (N=30) AD  nonresponder  (N=29) 
p 
Sex, m/f*  11/24  16/43      0.655 
     9/21  7/22  0.612 
Age, mean (SD)
† 61.8  (8.5) 60.3  (12.6)    0.882 
     60.90 (11.5) 59.70 (13.9) 0.940 
BMI, mean (SD)
‡ 24.9  (2.8) 24.1  (02.6)    0.111 
     24.10 (02.2) 24.00 (03.0) 0.867 
Onset age, mean (SD)
‡    55.40 (12.4) 51.10 (15.6) 0.244 
Episode numbers, mean (SD)
†     02.80 (03.3)  02.10 (01.1) 0.905 
Family history, Yes/No*      8/22  5/24  0.382 
Duration, months, mean (SD)
†     05.41 (05.5)  09.87 (10.5) 0.154 
*χ2 test,  †T-test,  ‡Mann-Whitney test. AD: antidepressant    
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and normal controls, respectively, p=0.111). 
When the serum S100B levels of antidepressant res-
ponders and nonresponders were compared at baseline, 
the S100B level of the responders was significantly higher 
than that of the nonresponders (68.6 ng/L for responders 
and 57.4 ng/L for nonresponders, p=0.048, Figure 1). 
After adjusting for sex, age, BMI, family history, number 
of episodes, onset age, and duration of the current episode, 
the baseline serum S100B levels of the responders were 
significantly higher than those of the nonresponders (lo-
gistic regression coefficient=0.05, χ
2=5.31, df=1, OR= 
1.05, 95% CI: 1.01-1.10, p=0.02). 
After 6 weeks of antidepressant treatment, the serum 
S100B levels of the antidepressant responders and non-
responders did not differ significantly (69.8±19.5 ng/L 
and 64.0±21.2 ng/L, mean±SD for responders and non-
responders, respectively, p=0.421, Figure 1). However, 
the serum S100B level increased after treatment with an-
tidepressants, and this increase was more prominent in 
nonresponders than in responders. Specifically, the mean 
serum S100B level of the non-responders increased by 6.6 
ng/L (57.4 ng/L to 64.0 ng/L), but the mean serum S100B 
level of the responders only increased by 1.2 ng/L (68.6 
ng/L to 69.8 ng/L). 
 
Discussion 
 
The results of this study indicate that the serum S100B 
levels did not differ between depressive patients and nor-
mal controls. However, depressive patients with high base-
line serum S100B levels responded better to treatment 
with antidepressants than those with low baseline serum 
S100B levels. In addition, the serum S100B level increased 
in response to treatment with antidepressants. 
In the present study, antidepressant responders had 
higher baseline serum S100B levels than non-responders. 
There are two causes of increased serum S100B levels, 
brain damage,
29 and functional secretion by astrocytes.
30 
Mathematical models suggest that serum S100B levels 
above 350 ng/L indicate brain damage.
31 In our study, the 
serum S100B levels were lower than 350 ng/L, which 
indicates that the levels observed in this study reflect 
functional secretion by astrocytes. S100B is known to have 
neurotrophic effects when it is present in response to func-
tional secretion.
13,32 For example, S100B enhances the 
growth and differentiation of neurons and astrocytes.
10,11,33 
In addition, S100B induces neurogenesis, which is essen-
tial to the behavioral effects of antidepressants.
5,34 The re-
sults of this study suggest that the baseline serum S100B 
level is associated with enhancement of the growth and 
differentiation of neurons, which results in a favorable 
therapeutic response to antidepressants. 
The results of previous studies comparing the serum 
S100B levels of depressive patients and normal controls 
showed that depressive patients had higher serum S100B 
levels than normal controls.
17,19,20,35 However, there was 
no difference in the serum S100B levels of depressive pa-
tients and normal controls observed in the present study. 
It is important to note that there were several differences 
between the patient populations of the present study and 
those of previously conducted studies. Specifically, the 
depressive patients enrolled in previous studies were in-
patients that had mean HAM-D scores that were greater 
than 25.
17,19,20,35 Conversely, in the present study, the pa-
tients were outpatients with a mean HAM-D score of 19. 
However, the results of a previous study revealed a po-
sitive correlation between the severity of depression and 
serum S100B levels in depressive patients.
35 This finding 
is similar to the results of the present study, in which there 
was a positive correlation between the HAM-D scores 
and the serum S100B levels (r=0.364, p=0.005). There-
fore, the difference in the results of the present study and 
previously conducted studies may stem from differences 
in the severity of depression in the patient populations. 
Another explanation for these differences may be the 
heterogeneity of neurotrophic activity in depressive pa-
tients. Neuroplasticity is disrupted in depression.
3 In res-
ponse, the brain attempts to restore neuroplasticity by 
increasing the S100B levels in depressive patients.
19 
However, the compensatory mechanism varies among de-
pressive patients.
19 As a result, some depressive patients 
have high concentrations of S100B, while others have low 
concentrations. Overall, the results of the present study 
indicate that the S100B levels of the depressive patients 
did not differ significantly from those of the normal con-
trols. Moreover, neurotrophic activity is an indicator of a 
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FIGURE 1. Comparison of serum S100B levels between antide-
pressant responders and nonresponders at baseline and after 6
week antidepressant treatment. Boxes represent means and error
bars represent standard deviations. Serum S100B level was sig-
nificantly higher in responders than in nonresponders at baseline.
*p<0.05.  
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compensatory response to disrupted neuroplasticity, which 
is related to antidepressant response.
36,37 Antidepressants 
exert their effects by increasing neurogenesis and modula-
ting the signaling pathways involved in neuroplasticity.
36,37 
Therefore, the levels of neuroplasticity in depressive pa-
tients can affect their response to antidepressants.
36,37 
We also found that the serum S100B level increased 
after antidepressant treatment. Antidepressants stimulate 
the secretion of neurotrophic factors, such as brain de-
rived neurotrophic factor (BDNF).
38 Antidepressants also 
enhance the secretion of S100B by astrocytes via seroto-
nergic systems.
15,39-41 Interestingly, in this study, the in-
crease in serum S100B levels in response to treatment with 
antidepressants was more prominent in nonresponders than 
in responders. Furthermore, in the present study patients 
with high baseline serum S100B levels were clinically 
improved within 6 weeks of treatment with antidepres-
sants, but the increases in their serum S100B levels during 
6 weeks of antidepressant treatment were minimal. Addi-
tionally, patients with low baseline serum S100B levels 
were not improved clinically within 6 weeks of treatment 
with antidepressants, but their serum S100B levels were 
much higher after 6 weeks of antidepressant treatment. 
In contrast to our findings regarding the levels of S100B, 
BDNF is known to increase more in responders than in 
nonresponders following antidepressant treatment.
38 These 
findings suggest that S100B and BDNF play different 
roles in the recovery of depression. One explanation is 
that S100B may be a prerequisite for neuroplastic changes 
that is required to improve depression, whereas BDNF 
may reflect the current state of recovery.
38 
There are several limitations to this study. First, various 
antidepressants were used in our study. However, all anti-
depressants exert an effect on neuroplasticity.
42 Second, 
the mean age of the patients included in this study was in 
the 60s, which is higher than that of other studies. Third, 
our study was a short-term clinical trial that was only con-
ducted for 6 weeks. Despite these limitations, this study 
is the largest serum S100B study performed in depressive 
patients to date and provides useful information regarding 
the relationship between serum S100B levels and depres-
sion. However, the results of this study need to be con-
firmed in a long-term depression study. In addition, fur-
ther studies including younger depressive patients using 
only one type of antidepressant are also needed. 
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